User profiles for "author:Lars Pedersen"

Lars C. Pedersen

- Verified email at niehs.nih.gov - Cited by 11280

Lars Pedersen

- Verified email at lundbeck.com - Cited by 5325

Lars Henning Pedersen

- Verified email at clin.au.dk - Cited by 4928

The Danish National Patient Registry: a review of content, data quality, and research potential

M Schmidt, SAJ Schmidt, JL Sandegaard… - Clinical …, 2015 - Taylor & Francis
Background The Danish National Patient Registry (DNPR) is one of the world's oldest
nationwide hospital registries and is used extensively for research. Many studies have …

The Danish Civil Registration System as a tool in epidemiology

M Schmidt, L Pedersen, HT Sørensen - European journal of epidemiology, 2014 - Springer
The methodological advances in epidemiology have facilitated the use of the Danish Civil
Registration System (CRS) in ways not previously described systematically. We reviewed …

Structure and function of sulfotransferases

M Negishi, LG Pedersen, E Petrotchenko… - Archives of biochemistry …, 2001 - Elsevier
Sulfotransferases (STs) catalyze the transfer reaction of the sulfate group from the ubiquitous
donor 3′-phosphoadenosine 5′-phosphosulfate (PAPS) to an acceptor group of …

Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism

J Christensen, TK Grønborg, MJ Sørensen, D Schendel… - Jama, 2013 - jamanetwork.com
Importance Valproate is used for the treatment of epilepsy and other neuropsychological
disorders and may be the only treatment option for women of childbearing potential …

[HTML][HTML] Incidence of adenocarcinoma among patients with Barrett's esophagus

F Hvid-Jensen, L Pedersen, AM Drewes… - … England Journal of …, 2011 - Mass Medical Soc
Background Accurate population-based data are needed on the incidence of esophageal
adenocarcinoma and high-grade dysplasia among patients with Barrett's esophagus …

Derivatives of erythropoietin that are tissue protective but not erythropoietic

M Leist, P Ghezzi, G Grasso, R Bianchi, P Villa… - Science, 2004 - science.org
Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through
interaction with different receptors. We generated receptor subtype–selective ligands …

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 …

G Salles, JF Seymour, F Offner, A López-Guillermo… - The Lancet, 2011 - thelancet.com
Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

M Hutchings, A Loft, M Hansen, LM Pedersen, T Buhl… - Blood, 2006 - ashpublications.org
Risk-adapted lymphoma treatment requires early and accurate assessment of prognosis.
This investigation prospectively assessed the value of positron emission tomography with 2 …

[HTML][HTML] Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus …

TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi… - 2012 - dukespace.lib.duke.edu
PURPOSE: Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit
lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by …

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway …

A Pottegård, LC Lund, Ø Karlstad, J Dahl, M Andersen… - bmj, 2021 - bmj.com
Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after
vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and …